Indefinite Delivery Contract SPE2DR25D9367

The U.S. Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide.

The IDC, valid through November 2026, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This contract enables the DLA to issue firm fixed-price delivery orders for these pharmaceutical items to support the medical supply requirements of Department of Defense (DoD) healthcare sites globally, including normal day-to-day operations, planned and unplanned contingencies, Prime Vendor Readiness, and War Readiness Materiel support. The original solicitation, expected to be issued in March 2024, aims to establish multiple Pharmaceutical Prime Vendor Global Program Generation V contracts with a total estimated value of $30.3 billion to provide worldwide pharmaceutical support to various DoD customers.